Conventional manufacturing of dosage forms for small molecule drugs in centralized facilities is not well-suited to meet the needs of adaptive clinical trials for early-phase dose escalation and ...
SAN JOSE, Calif.--(BUSINESS WIRE)--Xilinx, Inc. (NASDAQ: XLNX) today introduced the Kria™ portfolio of adaptive system-on-modules (SOMs), production-ready small form factor embedded boards that enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback